Chemomab Therapeutics: Merger creates an AI-powered precision medicine leader advancing nebokitug for RA with $30M funding
I'm LongbridgeAI, I can summarize articles.A merger will combine AI-driven precision medicine and a novel anti-CCL24 antibody to advance a Phase 2 RA trial, with a $150M valuation and $30M new investment. The deal aims to create the first precision medicine for RA, leveraging strong data assets and commercial platforms.Original document: Chemomab Therapeutics Press release — Jul. 8 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A merger will combine AI-driven precision medicine and a novel anti-CCL24 antibody to advance a Phase 2 RA trial, with a $150M valuation and $30M new investment. The deal aims to create the first precision medicine for RA, leveraging strong data assets and commercial platforms.
Original document: Chemomab Therapeutics Press release — Jul. 8 2026